RESET clinical trial results : Rivipansel flops in phase 3 trial in SCD

RESET clinical trial results : US pharma giant Pfizer’s rivipansel failed to meet the primary and key secondary efficacy endpoints of a phase 3 trial called RESET in sickle cell disease (SCD).

The aim of the RESET clinical trial was to assess the efficacy and safety of rivipansel in sickle cell disease patients, aged six and older, who were hospitalized for a vaso-occlusive crisis (VOC) and needed treatment with intravenous (IV) opioids.

The primary endpoint of the phase 3 sickle cell disease trial was time to readiness-for-discharge. On the other hand, the key secondary efficacy endpoints of the RESET clinical trial were time-to-discharge, time to discontinuation of IV opioids, and cumulative IV opioid consumption.

Commenting on the RESET clinical trial results of rivipansel, Brenda Cooperstone -Senior Vice President and Chief Development Officer, Rare Disease, Pfizer Global Product Development, said: “We are disappointed with the results, as we have been working in close partnership with the SCD community to advance rivipansel as a potential treatment option for acute VOC.

“We plan to share the study data at an upcoming scientific meeting as we want to ensure the learnings from this trial help inform future sickle cell programs that aim to improve care for SCD patients experiencing a VOC.

“We express our sincere gratitude to everyone who made this study possible, including the study investigators, and in particular, the patients and their families.”

RESET clinical trial results : Pfizer’s Rivipansel fails to meet primary endpoints and key secondary endpoints. Photo courtesy of w:ru:jenix89 (talk | contribs) and Wikipedia.org.

The RESET clinical trial had enrolled 345 patients, who were randomly grouped 1:1 to be treated with rivipansel or placebo, which were intravenously administered every 12 hours to a maximum of 15 doses. All the participants of the RESET clinical trial were followed for safety for 35 days after the completion of the last dose of rivipansel.

Freda Lewis-Hall – Chief Patient Officer and Executive Vice President, Pfizer, commenting on the RESET clinical trial results of rivipansel, said: “We recognize this is a significant setback for the SCD community, who are eagerly awaiting new treatment options, and we share in their disappointment.

“Many of us have witnessed first-hand the devastating impact of SCD on patients and their families, but we have also been moved by their incredible strength and bravery, and we will continue to support this courageous community.”

For more clinical trial news like the RESET clinical trial results of rivipansel, keep following Pharma News Daily.

Related posts

• TRACON begins phase 1 TJD5 clinical trial in advanced solid tumors (0)
• Daiichi Sankyo bags Turalio FDA approval for tenosynovial giant cell tumor (0)
• Bayer, Orion secures Darolutamide FDA approval for prostate cancer (0)
• MONARCH 2 clinical trial results : Verzenio, fulvestrant combo improves overall survival in metastatic breast cancer (0)
• Mylan Upjohn merger : Pfizer to merge off-patent drugs unit with Mylan (0)
• Janssen’s Ponesimod OPTIMUM trial in MS meets primary endpoint (0)
• Boehringer Ingelheim secures Ofev FDA approval recommendation for SSc-ILD (0)
• NeuroVive secures NeuroSTAT FDA fast track designation for TBI (0)
• Aptar wins FDA approval for Unidose Powder System for nasal spray of hypoglycemia drug (0)
• Proteostasis begins dosing in phase 2 cystic fibrosis trial (0)

The post RESET clinical trial results : Rivipansel flops in phase 3 trial in SCD appeared first on PharmaNewsDaily.com.